Abstract: Objective  To explore the risk factors and drug resistance of Carbapenemresistant Enterobacter(CRE) in malignant tumor patients  to provide a basis for the prevention and treatment of hospital infection. Methods  A retrospective analysis of 82 malignant tumors patients infected with CRE from January 2014 to December 2018 was conducted and the drug resistance was also analyzed. Besides, 165 cases of malignant tumors patients sensitive to  CRE  infection were selected as the control group. Then, logistic regression analysis was carried out  to investigate infection risk factors. Results  All patients with CRE showed a high drug resistance to cefepime and amoxicillin/clavulanic acid (>90%), and klebsiella pneumoniae had a high drug resistance to ceftriaxone and ceftazidime (>90%). And, Escherichia  coli  showed a high drug resistance to ceftriaxone (93.1%). In addition, CRE was highly sensitive to tigecycline, among which Klebsiella pneumoniae was 92.7% and the rest was 100%. Escherichia coli in CRE also had a good sensitivity to amikacin (72.4%). Logistic multiplefactor regression analysis indicated that previous use of carbapeem antibiotics was the independent risk factor for patients infected with CRE. Conclusion  CRE patients with malignant tumors have a good sensitivity to tigecycline and a high drug resistance rate. Age (great than or equal to 60 years old), chemotherapy, combined diabetes and previous use of carbapeem antibiotics are the risk factors for CRE infection. A previous use of carbapeem antibiotics is the independent risk factor for the CRE infection of malignant tumors patients. Therefore, the department of hospital infection should purposefully strength prevention and control.

Key words: enterobacteriaceae infections; , carbapenemresistant, drug resistance, risk factors